viewe-Therapeutics PLC

e-Therapeutics completes placings to raise £40mln


e-Therapeutics (LON:ETX) has wrapped up its two placings, raising £40mln for the drug discovery and development company.

It comes after the company gained the backing of shareholders for the equity issue, meaning that the second placing of 120.25mln shares could be completed.

The new shares were placed at 32p each, a premium of 1.25p to the market price of e-Therapeutics at the close of the day before the fund raising was announced.

Following the proposed issue, which needs to be ratified by shareholders, the company will have pro-forma net cash and liquid resources of about £48 million.

The company believes it now has enough money to carry out all its planned discovery and development activities into 2017, at which point the company believes it should have a licensing deal in the bag for its lead cancer drug, ETS2101.

Early and very limited results from e-Therapeutics’ phase I trial of ETS2101 have not yet revealed any “dose limiting toxicities” or other adverse effects.

So far, 12 patients have been given low doses of the treatment in phase I studies, which are designed to test the safety and tolerability. The amount administered will be increased over time.

Shared edged 2.4% lower this morning.


Quick facts: e-Therapeutics PLC

Price: 20 GBX

Market: AIM
Market Cap: £84.15 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...


2 min read